These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, ...

These drugs, called GLP1-RAs (short for glucagon-like peptide-1 receptor agonists), have been found to reduce hospital visits ...

Long-term weight stability is recommended to improve health outcomes in individuals with type 1 diabetes. Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional ... It also ranks No. 1 in New York according to Newsweek ...

Diabetic nephropathy is a progressive kidney disease associated with diabetes mellitus – type 1 and type 2 – affecting kidney glomeruli, arterioles, tubules and the interstitium. Clinical ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI ...